|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Phospholamban (PLB) inhibits SERCA2 activity and is therefore a potential target to improve the cardiac performance in heart failure.
|
10468529 |
1999 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phospholamban deficiency may prevent such left ventricular dysfunction and its progression to heart failure in some of the animal models with dilated cardiomyopathy.
|
11855657 |
2001 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phospholamban (PLN) inhibition enhances calcium cycling and is a potential novel therapy for heart failure (HF).
|
27811197 |
2017 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phospholamban (PLN) p.Arg14del cardiomyopathy is associated with an increased risk of malignant ventricular arrhythmias and severe heart failure and a poor prognosis from late adolescence.
|
28759816 |
2018 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A mutation in the coding region of the phospholamban (PLN) gene (R14del) is identified in families with hereditary heart failure.
|
25923014 |
2015 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormalities in two proteins that regulate Ca(2+) handling in myocytes, phospholamban and the voltage-dependent L-type Ca(2+) channel, were also reversed, as was the increased expression of genes that are associated with heart failure.
|
16893886 |
2006 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.
|
12134142 |
2002 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization-activated cyclic nucleotide-gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs.
|
28352365 |
2017 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein we focus on hereditary mutants of phospholamban that are associated with heart failure, such as Arg(9)-Cys, Arg(9)-Leu, Arg(9)-His, and Arg(14)-deletion.
|
25563649 |
2015 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to reported benefits of PLN ablation in mouse heart failure, humans lacking PLN develop lethal dilated cardiomyopathy.
|
12639993 |
2003 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, PLB, troponin I (TnI) and PP1 protein and TnI phosphorylation levels did not differ between HF and NF.
|
14732205 |
2004 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, steady-state levels of phospholamban mRNA decreased, whereas levels of beta-myosin heavy-chain mRNA were unchanged with heart failure.
|
2040039 |
1991 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, transgenic mice that express an inducible Galpha q mutant that cannot activate phospholipase Cbeta (PLCbeta) do not develop heart failure or changes in PLB phosphorylation, but do show decreased L-type Ca2+ current density.
|
16210321 |
2005 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, our objective was to determine the presence of the -36A>C alteration in PLN gene in a Brazilian population of individuals with HF and to test whether this alteration is associated with heart failure or with a worse prognosis of patients with HF.
|
19638213 |
2009 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this work, we have designed and synthesized an aptamer-based near-infrared fluorescence nanoprobe for fluorescence imaging of phospholamban (PLN), which is an intracellular micropeptide that affects calcium homeostasis, and is closely associated with human heart failure in the clinic.
|
30777430 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations and post-translational modifications of PLN may lead to dilated cardiomyopathy (DCM) and heart failure.
|
29501609 |
2018 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the phospholamban (PLN) gene are associated with dilated cardiomyopathy (DCM) and severe heart failure.
|
26917049 |
2016 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the gene encoding PLN have been associated with idiopathic dilated cardiomyopathy; however, no systematic search for PLN mutations in heart failure has been conducted.
|
22137083 |
2011 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
One compound increases SERCA2a calcium affinity in cardiac membranes but not in skeletal, suggesting that the compound is acting specifically on the SERCA2a-PLB complex, as needed for a drug to mitigate deficient calcium transport in heart failure.
|
30135432 |
2018 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic variants in human phospholamban coding gene (PLN) are known to cause hereditary dilated cardiomyopathy with heart failure in an autosomal dominant mode.
|
30638982 |
2019 |
|
Congestive heart failure
|
0.400 |
Therapeutic
|
disease |
RGD |
Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.
|
22947202 |
2012 |
|
Congestive heart failure
|
0.400 |
Therapeutic
|
disease |
RGD |
Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCα/β2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent.
|
22970977 |
2012 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting phospholamban by gene transfer in human heart failure.
|
11864915 |
2002 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The p.Arg14del founder mutation in the gene encoding phospholamban (PLN) is associated with an increased risk of malignant ventricular arrhythmia (VA) and heart failure.
|
29635323 |
2019 |